CD47 and anemia (phenotype): Although the use of priming and maintenance dose of magrolimab helped reduce anaemia as observed in the first clinical trials, the recent halt on the magrolimab ENHANCE trials in AML/MDS patients highlights the pivotal need to develop strategies that further mitigate toxicity in order to unlock the immune (re)activation potential of CD47‐SIRPα therapy.